Mutating Antibodies for Easier Drug-Conjugate Manufacturing
Scientists at Johns Hopkins University have engineered a general‑purpose antibody by mutating its fragment crystallizable (Fc) region, creating up to four new attachment sites for molecules such as drugs, dyes, or nanoparticles. Six precise Fc mutations enable consistent, site‑specific conjugation, addressing the heterogeneity that hampers antibody‑drug conjugate (ADC) manufacturing. The team demonstrated the platform by attaching fluorescent dyes and coating nanoparticles, showing reliable quantification of available sites and efficient cargo delivery into target cells. This tunable system could simplify ADC production and expand research applications.
In the Clinic for May 20, 2026
The May 20, 2026 clinic roundup aggregates the latest clinical trial readouts and publications from a cross‑section of biopharma and med‑tech firms, including Boston Scientific, Sanofi, and emerging players like Elixir and Sensome. Companies disclosed early‑stage data on cardiovascular devices, oncology immunotherapies,...
FDA Sends Warning Letter After Chinese Supplier Breaks GLP-1 Import Restrictions
The FDA issued a warning letter to Harbin Jixianglong Biotech after inspectors found the Chinese API maker importing semaglutide from a non‑green‑list source and mislabeling it as produced in‑house. Jixianglong had been added to the FDA’s newly created “green list”...
WVE-006 RNA Editing Therapy Achieves MZ-Like Phenotype in Alpha-1 Antitrypsin Deficiency Phase 1b/2a Trial
Wave Life Sciences reported that its investigational RNA‑editing drug WVE‑006 generated major‑variant alpha‑1 antitrypsin (M‑AAT) levels comparable to the protective heterozygous Pi*MZ phenotype in patients with homozygous Pi*ZZ AAT deficiency. The Phase 1b/2a RestorAATion‑2 trial showed 64%–59% of circulating AAT was...
EQS-News: GeoVax Comments on Escalating Bundibugyo Ebola Outbreak and Growing Need for Flexible Biodefense Vaccine Platforms
GeoVax Labs warned that the escalating Bundibugyo Ebola outbreak in Central Africa highlights the lack of licensed vaccines for less‑common Ebola strains. The company pointed to its Modified Vaccinia Ankara (MVA) platform, which has shown single‑dose protection against Zaire and...
Why Patient Engagement Is Clinical Trials’ Next Strategic Frontier
The article argues patient engagement is the next strategic priority for clinical trials, especially as decentralized and hybrid models reduce face‑to‑face contact. Simple reminder emails are insufficient; effective engagement requires tailored gamification, real‑time financial incentives, and transparent feedback showing participants...
Beam One-Ups Wave as Both Show Promise of Editing for AATD
Beam Therapeutics presented Phase 1/2 data for its DNA editor BEAM‑302, showing an 80% drop in mutated alpha‑1 antitrypsin (AAT) protein and lifting total AAT above the 11 µM protective threshold, with effects lasting 12 months. Wave Life Sciences reported its RNA editor...
AbbVie’s New Immunology Standard-Bearer Skyrizi Kneels to UCB’s Bimzelx in Psoriatic Arthritis
UCB’s Bimzelx outperformed AbbVie’s Skyrizi in a Phase 3 head‑to‑head trial for psoriatic arthritis, achieving 49.1% ACR50 versus 38.4% for Skyrizi at week 16. While Bimzelx also showed numerically higher minimal disease activity (43% vs 39.9%), the difference missed statistical significance. Skyrizi...
Clinical Trials Day 2026: ‘Research Rising’ Theme Reflected in Q1 Study Growth
Clinical Trials Day 2026 highlighted a 1.3% rise in global Phase I‑III trial initiations in Q1, with China accounting for one‑third of the new studies and posting a 6.5% year‑on‑year increase. Europe and the United States also accelerated, growing 9.8%...
QIAGEN and NVIDIA Partner on AI Drug Discovery
Qiagen’s Digital Insights division will embed NVIDIA’s accelerated computing and BioNeMo platform into its bioinformatics suite, creating a graph‑based AI environment for drug discovery. The integration is designed to streamline target identification, biomarker discovery, and multi‑omics hypothesis generation for pharma...
BioMarin’s ENERGY 3 Trial of BMN 401 Meets One Co-Primary Endpoint
BioMarin Pharmaceutical announced that its Phase III ENERGY 3 trial of BMN 401 met one of two co‑primary endpoints, showing a statistically significant rise in plasma inorganic pyrophosphate (PPi) levels in children with ENPP1 deficiency through week 52. The trial failed to demonstrate any...
Proactivity for Drug Safety: A New Service or a New Mindset?
The letter argues that proactive drug‑safety surveillance cannot fix a system that approves drugs with insufficient benefit data and overlooks rare, severe harms. It cites historic delays in risk‑management actions for valproate and topiramate, noting that formal REMS were only...
Tuneable Peptide Biotech Parabilis Files IPO
Parabilis Medicines, the Cambridge‑based tuneable peptide biotech, filed a Nasdaq prospectus to raise roughly $100 million in an IPO under the PBLS ticker. The offering follows a $305 million private round and a multi‑billion‑dollar alliance with Regeneron, which contributed $50 million upfront and...
Atossa Therapeutics, Inc. (ATOS) Discusses Challenges in Breast Cancer Drug Development and Innovation in Clinical Research Transcript
Atossa Therapeutics used a May 19, 2026 analyst call to outline its lead breast‑cancer candidate, Z‑endoxifen. CEO Steven Quay and UCSF oncology pioneer Dr. Laura Esserman discussed the scientific hurdles of endocrine‑resistant disease and the company’s push for innovative trial designs. The conversation...
The BioPharm Brief: Smarter Platforms, Safer Therapies, AI Acceleration
Biopharma firms are accelerating the adoption of next‑generation platforms to boost therapeutic precision and speed. JCR Pharmaceuticals unveiled preclinical data for its JUST‑AAV system, which enhances central nervous system delivery while limiting liver exposure. Hansa Biopharma signed a deal worth...
New Shell Helps Gold Nanoparticles Keep Shape Under Laser Heat Longer
Researchers from Córdoba, Strasbourg and the Sorbonne have developed a polymer‑based shell that preserves the distinctive bipyramidal shape of gold nanoparticles during laser‑induced heating. The protective layer outperforms traditional sodium citrate ligands, keeping the particles stable longer and maintaining their...
Sustained Therapeutics – Presents Positive Phase 2 Data for ST-01 in Podium Presentation at the American Urological Association 2026 Annual...
Sustained Therapeutics presented Phase 2 data showing its ST‑01 polymer‑lidocaine formulation significantly reduced pain in men with chronic scrotal content pain (CSCP). At the 70 mg/mL dose, 67% of patients achieved a ≥2‑point pain reduction and 83% met clinical response criteria, far...
Why the Need to Expand Industry Focus Beyond Gene Editing Toward Scalable Cell Therapy Manufacturing?
Cell therapy developers are moving beyond pure gene‑editing breakthroughs to prioritize scalable manufacturing, according to Cellular Origins CEO Dr. Edwin Stone at the 2026 ASGCT meeting. The industry is integrating manufacturing feasibility into early‑stage development, evaluating multiple delivery platforms such...
BioMarin Drug Acquired in Buyout Misses Goal in Rare Disease Study
BioMarin Pharmaceutical’s BMN 401, an enzyme‑replacement therapy for ENPP1 deficiency, met its primary biochemical endpoint by raising plasma PPi levels but failed the co‑primary skeletal health goal in a Phase 3 trial of 27 children. The miss on clinical benefit and all...
Lessons Learned From Drug Development Programs in Autism: Implications for Future Programs
The article synthesizes expert insights on why autism drug development has lagged, highlighting the lack of approved therapies for core symptoms and the challenges posed by biological and clinical heterogeneity. It outlines six key learnings, including the need to measure...
Wave Aims for Monthly Dosing with RNA Editing Treatment for AATD
Wave Life Sciences announced an updated read‑out from its early‑stage trial of an RNA‑editing therapy for alpha‑1 antitrypsin deficiency (AATD). The data indicate that the treatment can restore functional protein levels with a dosing schedule that could be moved to...
Relay Doubles the Bar, Outpacing Novartis with a 60% Response in Rare Disease
Relay’s oral PI3Kα inhibitor zovegalisib posted a 60% volumetric response in a Phase 2 trial of patients with vascular malformations, far outpacing Novartis’ 11% result with Vijoice. The data, presented at the ISVAA World Congress 2026, came from 20 evaluable patients,...
STAT+: A New Ranking of Pharma Companies by R&D Performance
Eli Lilly topped IDEA Pharma’s annual R&D ranking, ranking first in both the Innovation and Invention categories—a first in the study’s history. The Innovation score reflects revenue from newly launched drugs, while the Invention score weighs the size of the pipeline...
EMA Marketing Authorization of New Drugs in April 2026
In April 2026 the European Medicines Agency granted marketing authorizations and CHMP positive opinions for a slate of new therapies spanning infectious disease, neurology, immunology, endocrinology and rare disorders. Merck’s Enflonsia monoclonal antibody reduced RSV‑related hospitalizations by 84% in infants,...
Sourav K. Mishra, M.D. / All India Institute of Medical Sciences - 724881 - 04/29/2026
The FDA issued a warning letter to Dr. Sourav K. Mishra of AIIMS Bhubaneswar for serious violations in a bioequivalence study of doxorubicin hydrochloride liposome injection conducted for Qilu Pharmaceutical. The investigator administered the prohibited CYP3A4 inhibitor aprepitant to all...
RAS Inhibition Enters Its Second Wave
RAS inhibition has moved into a second wave of drug development that goes beyond the KRAS G12C breakthrough. After sotorasib and adagrasib secured accelerated approvals for non‑small cell lung cancer and later for KRAS G12C‑mutated colorectal cancer, companies are targeting more prevalent...
Vincentage Pharma Reports Topline P-III Trial Data on VCT220 for Weight Management
Vincentage Pharma announced topline results from its pivotal Phase III trial of VCT220, a GLP‑1 agonist, in 840 Chinese adults with obesity or overweight plus a comorbidity. Over 52 weeks, the 120 mg and 160 mg doses produced mean weight losses of 12.2%...
FDA Approves First-Ever Gene Therapy For Deafness, Opening Door To New Era
The U.S. Food and Drug Administration has approved the world’s first gene therapy for deafness, targeting the OTOF mutation that blocks sound transmission in the inner ear. In a pivotal trial of 20 children and teens, 80% experienced improved hearing...
In the Clinic for May 19, 2026
BioWorld’s May 19, 2026 clinic roundup aggregates a wide array of industry snapshots, special reports, and infographics covering biopharma, med‑tech, and emerging health topics. The collection highlights trends such as dynamic digital data analysis, the 2026 med‑tech outlook, mRNA vaccine research, and...
BioMarin Suffers Another Blow to Rare Disease Portfolio in Phase 3 Flop
BioMarin’s investigational enzyme replacement therapy BMN 401 lowered plasma inorganic pyrophosphate (PPi) in the Phase 3 ENERGY 3 trial for ENPP1 deficiency, but it did not translate into clinical benefit. The study enrolled almost 30 children aged 1‑12 and missed the primary Radiographic...
Bayer’s Hyrnuo (Sevabertinib) Gains the US FDA Priority Review for 1L Treatment of HER2-Mutated NSCLC
Bayer’s Hyrnuo (sevabertinib) received FDA priority review for first‑line treatment of adults with locally advanced or metastatic non‑small cell lung cancer (NSCLC) harboring HER2 kinase‑domain activating mutations and no prior systemic therapy. The review follows promising interim data from Cohort F...
Brepocitinib Approval May Be ‘Highlight of the Derm-Rheum World’
The FDA has set an Aug. 29 PDUFA date for brepocitinib, a first‑in‑class oral TYK2/JAK1 inhibitor, as a potential therapy for dermatomyositis. In the 52‑week VALOR phase‑3 trial, the drug outperformed placebo on skin and muscle outcomes and enabled significant glucocorticoid...
First Healthy Volunteers Receive TRIV-573 Doses in Triveni Bio’s Phase I Trial
Trivena Bio has dosed its first healthy volunteers in a Phase I trial of TRIV‑573, a half‑life‑extended bispecific antibody that simultaneously inhibits kallikreins 5/7 and blocks interleukin‑13. The dual‑target approach is designed to repair the skin barrier while curbing inflammation in moderate‑to‑severe...
Common Asthma Drug May Turn Off Tumor 'Switch' Tied to Immunotherapy Resistance
A Northwestern Medicine study published in Nature Cancer shows that blocking the cysteinyl leukotriene receptor 1 (CysLTR1) with the asthma drug montelukast can reverse immunotherapy resistance in several aggressive cancers. Experiments in mouse models and analyses of human tumor samples demonstrated...
Vaccine Experts Debate Options to Combat Outbreak of Unusual Ebola Strain
The World Health Organization convened a closed meeting of vaccine experts after the Bundibugyo ebolavirus outbreak in the Democratic Republic of the Congo was declared a public‑health emergency. The outbreak has produced roughly 500 suspected cases and more than 130...
New Therapies Could Help Type 1 Diabetes Care Move Beyond Insulin Alone
A recent review in The Journal of Clinical Investigation outlines emerging disease-modifying therapies for type 1 diabetes that aim to preserve beta‑cell function alongside insulin. The anti‑CD3 antibody teplizumab showed a single 14‑day course can postpone clinical onset by up to...
What’s Next for FDA
The Biden administration swiftly removed most of the ideological appointees installed by former FDA commissioner Marty Makary, reinstating career officials to restore institutional norms. HHS advisor Chris Klomp led the overnight purge, signaling a shift from political loyalty to administrative competence....
Immune Checkpoint Regulation in Cancer Therapy and Evasion
The article reviews the multilayered regulation of immune checkpoint molecules, detailing genetic, epigenetic, transcriptional, post‑transcriptional, translational, and post‑translational mechanisms that shape checkpoint expression in tumors and immune cells. It highlights the recent clinical integration of LAG3‑targeted therapies as the newest...
MHRA’s Pound on Aligning Clinical Trial Regulation with Innovation
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) is rolling out clinical‑trial reforms aimed at more than just faster approvals. Interim director of innovation James Pound says the agency is pursuing international alignment and horizon‑scanning to anticipate emerging therapies....
New Math Method Inflates Alzheimer’s Drug Success by 29x
A Brown University research letter published in JAMA Neurology warns that the statistical technique known as quantile aggregation can dramatically overstate the efficacy of emerging Alzheimer’s drugs. Simulations showed the method inflates the perceived link between amyloid clearance and cognitive...
SCOTUS Rejects Pharma Companies’ Petitions To Review IRA Drug Program
The U.S. Supreme Court on May 18 denied six pharmaceutical companies’ petitions to revisit lower‑court rulings that upheld the Inflation Reduction Act’s (IRA) Medicare drug‑price negotiation program. The decision ends the companies’ multi‑year legal challenge, leaving the federal government’s authority...
Coya 302 Gets Fast-Track Designation for ALS Treatment
Coya Therapeutics received FDA fast‑track designation for its experimental ALS drug Coya 302, a subcutaneous blend of low‑dose IL‑2 and CTLA‑4 immunoglobulin. The therapy is designed to boost regulatory T‑cells while suppressing inflammatory monocytes, addressing the immune imbalance that accelerates motor‑neuron...
More Than 5 Million US Adults Could Benefit From Lp(a)-Targeted Therapies
New analysis presented at ACC.26 estimates over 5.3 million U.S. adults with ASCVD and Lp(a) ≥ 70 mg/dL could qualify for emerging Lp(a)-lowering therapies. Modeling suggests a 10‑30% relative risk reduction could prevent 123,000‑368,000 recurrent cardiovascular events over five years, roughly 25,000‑74,000 per year....
Atara Bounces Back with FDA
Atara Biotherapeutics saw its shares nearly double on May 7 after the FDA outlined a path for resubmitting its cell‑therapy candidate, tabelecleucel. The agency agreed to accept the single‑arm trial data in exchange for additional long‑term follow‑up, easing the regulatory deadlock...
PASSAGE Trial Shows Tezepelumab Benefit in Diverse Asthma Groups: Njira L. Lugogo, MD, MS
The phase 4 PASSAGE trial evaluated tezepelumab in severe, uncontrolled asthma and reported a 70% reduction in annualized asthma exacerbation rate overall, with 54‑77% reductions across all phenotypes. The study included underrepresented groups such as smokers, patients with COPD, Black individuals,...
MSD's Sac-TMT Delivers in First Phase 3 Readout
Merck (MSD) reported that its TROP2‑targeting antibody‑drug conjugate sacituzumab tirumotecan (sac‑TMT), licensed from China’s Kelun‑Biotech, improved progression‑free and overall survival in a phase 3 trial for advanced or recurrent endometrial cancer. The TroFuse‑005 readout marks the first pivotal data for sac‑TMT...
Merck's ADC Sac-TMT Gets Its First Global Phase 3 Win Ahead of Schedule
Merck and China‑based Kelun‑Biotech announced that their experimental antibody‑drug conjugate sac‑TMT achieved its primary endpoint in a global Phase 3 trial, completing ahead of schedule. The study enrolled roughly 650 patients with advanced solid tumours across 12 countries and demonstrated a...
Sotatercept Reduced Morbidity in CTD-PAH Analysis: Rogerio Souza, MD, PhD
A pooled analysis of the phase‑3 STELLAR, ZENITH and HYPERION trials shows that sotatercept significantly lowers the risk of first major morbidity or mortality events in patients with connective tissue disease‑associated pulmonary arterial hypertension (CTD‑PAH). The benefit persisted despite most...
FDA Approves Baxdrostat for Inadequately Controlled Hypertension
AstraZeneca’s Baxdrostat (Baxfendy) received FDA approval as the first aldosterone synthase inhibitor for hypertension in the United States. The drug is indicated for patients whose blood pressure remains uncontrolled despite taking at least two other antihypertensive agents. Phase III trials (BaxHTN...
How Advanced Analytics Partnerships Enhance the Biopharma Value Chain
Strategic biopharma alliances are increasingly embedding multimodal AI across the entire drug‑development pipeline. Partnerships leverage foundation models to sharpen biomarker discovery and patient selection for complex modalities such as antibody‑drug conjugates. Large‑scale genomic and clinical datasets enable virtual cell modeling...